Esperion Therapeutics (ESPR) said Tuesday that its bempedoic acid has been submitted by Otsuka Pharmaceutical to the Japanese Ministry of Health, Labour, and Welfare for approval to treat hypercholesterolemia and familial hypercholesterolemia.
Esperion said the submission was based on preliminary results from a late-stage study, in which bempedoic acid showed statistical significance in reducing LDL-C compared to placebo.
Otsuka acquired exclusive development and commercialization rights for bempedoic acid in Japan from Esperion in 2020, Esperion said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。